CD34 and Miyoshi myopathy: In another, single-arm, open-label, dose-escalation study (NCT01010880), motixafortide administered before ASCT to patients with MM undergoing standard HSPC mobilization was safe, well tolerated and led to significant increases in PB CD34+ HSPCs.